title: Could treatment with R-HCVAD/R-MA as compared to R-CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma?
authors.affiliation: Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. daniel.landsburg@uphs.upenn.edu.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Landsburg
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Schuster
authors.forename: Jakub
authors.initials: J
authors.lastname: Svoboda
authors.forename: Sunita D
authors.initials: SD
authors.lastname: Nasta
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male
keywords: CHOP; CVAD; MYC; chemotherapy; lymphoma